XML 75 R26.htm IDEA: XBRL DOCUMENT v3.6.0.2

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Schedule of Significant Balance of Accounts Receivable

The Company has not experienced any loss on its deposits of cash and cash equivalents. Included in current assets are significant balances of accounts receivable as follows:

		As of December 31,
		2016				2015
Astellas Pharma Inc. (“Astellas”)—Related party			39	%			29	%
AstraZeneca AB (“AstraZeneca”)			61	%			71	%

X

- Definition

Schedule of accounts receivable due from collaborating partners.

+ References

No definition available.

+ Details

Name:	fgen_ScheduleOfAccountsReceivableDueFromCollaboratingPartnersTableTextBlock
Namespace Prefix:	fgen_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_AccountingPoliciesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration